Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ototoxicity 1Osteosarcoma 1Neoplasms 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pantoprazole × Sarcoma × Clear all
NCT01848457 2020-03-16

Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

Children's Hospital of Philadelphia

Phase 2 Completed
13 enrolled 15 charts
Sarcoma

Ototoxicity, Neoplasms, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡